Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00168545
Other study ID # NOVO-2624-Twodose2_immunology
Secondary ID NOVO-2624LÆGEVID
Status Completed
Phase Phase 4
First received September 9, 2005
Last updated September 21, 2011
Start date January 2006
Est. completion date January 2007

Study information

Verified date September 2006
Source Bandim Health Project
Contact n/a
Is FDA regulated No
Health authority Guinea-Bissau: Ministry of HealthGambia: MRC Ethics Committee
Study type Interventional

Clinical Trial Summary

OBJECTIVES

- General: To investigate the immunological background for the non-specific effects of diphtheria-tetanus-pertussis (DTP) and measles vaccines on child mortality

- Specific: Examine the cytokine responses and possible association with morbidity in a study of DTP vaccinated children who will be randomised to receive a measles vaccine or no vaccine at 4½ months of age. (All children will receive a measles vaccine at 9 months of age)


Description:

Non-specific effects of vaccines The idea of vaccines having non-specific effects was first proposed in 1991 from a study in Senegal, West Africa. It was discovered that children receiving high-titre measles vaccine (HT) at 6 months of age had higher mortality than children who received the standard titre measles vaccine (STD) at 9 months of age. The difference was found only for girls. A study from Haiti confirmed the effect. Since children vaccinated with HT had lower mortality than their equivalents who had not received any measles vaccine, the difference in mortality between recipients of HT vaccine and STD vaccine was explained by a non-specific beneficial effect of the STD measles vaccine rather than a harmful effect of the HT vaccine. The non-specific beneficial effect of STD measles vaccine on child mortality has been reconfirmed in many data-sets.

Also the BCG vaccine is associated with striking effects on child mortality reducing mortality by about 50%. Further, among BCG vaccinated children, having a BCG scar or a positive tuberculin reaction was associated with about 55% lower mortality in the following 12 months than among children who had a negative tuberculin reaction or who did not have a BCG scar.

The effect of OPV is difficult to separate from the effects of BCG and DTP vaccines since OPV is normally given together with these vaccines. There have, though, been some periods without DTP in Bissau due to global shortage of vaccines, and we have compared the case fatality at the hospital for children who received only OPV and children who received both the prescribed OPV and DTP. Children having received OPV had 3-fold lower mortality than children having received both vaccines. Data from an OPV vaccination campaign that took place in Guinea-Bissau also suggested a non-specific beneficial effect for the recipients. Further, studies from Chile and the Soviet Union have suggested that OPV had a beneficial effect on mortality and morbidity.

In contrast, DTP, HBV and inactivated polio vaccine (IPV) seem to exert a non-specific detrimental effect on child mortality, although the findings on DTP were considered controversial by a recent review. Current studies indicate that the negative effect of DTP may be neutralized by a subsequent measles vaccination. It is striking that all the vaccines with a non-specific beneficial effect are live, whereas the vaccines with an apparently harmful effect are killed. Results from animal studies have shown that attenuated live vaccines tend to induce a Th1 response and offer better protection against severe disease than the corresponding inactivated vaccines, which tend to induce a Th2 response. So far, very few studies have examined whether these effects differ between male and female animals. One study reported that BCG-vaccinated female mice were better protected against malaria parasites than male mice (31). There is therefore an urgent need to conduct studies that can help uncover the immunology behind the non-specific effects.

Sex-specific effects All epidemiological studies carried out so far confirms the observation that non-specific effects are sex-specific. Live vaccines (measles, BCG, OPV) have a beneficial effect that is particularly good for girls whereas inactivated vaccines (DTP, HBV, IPV) have a negative effect for girls. To date, there are no immunological studies which have examined whether routine vaccines affect the immune system differently for boys and girls.

We thus propose to study, in a randomised controlled trial of measles vaccination taking place in Guinea-Bissau, the immunology of non-specific effects of vaccination, and their interaction with sex. Specifically, among children who have received the 3 recommended doses of DTP, we will be able to compare the cytokine and antibody profiles of children who receive an early dose of measles vaccine at 4½ months of age with children who receive no additional vaccine at this age.


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date January 2007
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 4 Months to 9 Months
Eligibility Inclusion Criteria: A sub-cohort of children participating in the study "MEASLES VACCINATION IN GUINEA-BISSAU. STRATEGIES TO REDUCE DISEASE BURDEN AND IMPROVE CHILD SURVIVAL", protocol ID: RUF-91134-2601-Twodose2.

Exclusion Criteria: Severe illness

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Biological:
Measles vaccine


Locations

Country Name City State
Guinea-Bissau Bandim Health Project Bissau Apartado 861

Sponsors (6)

Lead Sponsor Collaborator
Bandim Health Project Danish Council for Development Research, Fonden til Lægevidenskabens Fremme, Leiden University Medical Centre, DEPT of Parasitology, Leiden Holland, Medical Research Council Unit, The Gambia, Novo Nordisk A/S

Country where clinical trial is conducted

Guinea-Bissau, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cytokine levels in the randomised groups
See also
  Status Clinical Trial Phase
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Completed NCT02538211 - The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses N/A
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01689324 - Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents Phase 1/Phase 2
Completed NCT01444781 - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants Phase 3
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00804284 - Database Surveillance Safety Study of PENTACEL® Vaccine N/A
Completed NCT00534833 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Phase 3
Completed NCT00514709 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants Phase 3
Completed NCT00379977 - Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age Phase 3
Completed NCT00772369 - Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Phase 4
Completed NCT00879827 - Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants Phase 3
Completed NCT01457495 - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly Phase 2
Completed NCT01267058 - Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults Phase 3
Completed NCT02853929 - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Phase 4
Completed NCT02858440 - A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Phase 3
Recruiting NCT06049940 - Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population Phase 3
Completed NCT00385255 - Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults Phase 3